Autism

PaxMedica CEO Interviewed by The BRAIN Foundation

Webcast Link Available at PaxMedica.com TARRYTOWN, NY, June 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD),…

12 months ago

Bionano Announces Peer-Reviewed Publication on the Utility of Combining OGM and a 523-gene NGS Panel for Standard Evaluation of Myeloid Cancers

SAN DIEGO, June 20, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), today announced the publication in Cancers of a peer-reviewed…

12 months ago

Axial Therapeutics Receives Second Research Grant Award from The Michael J. Fox Foundation to Further Support Advancement of AX-5006 for Parkinson’s Disease

–Grant supports the continued preclinical development of AX-5006, a small molecule, gut-restricted amyloid inhibitor for symptomatic treatment and modification of…

12 months ago

PaxMedica Submits Clinical Trial Request in Autism Spectrum Disorder

ASD-101 protocol submitted to SAHPRA, South Africa’s regulatory agencyPAX-101 internally developed supply chain entering final stagesTARRYTOWN, NY, June 14, 2023…

12 months ago

Bionano Announces Presentation of OGM Utility Across Stem Cell Therapy Applications at the International Society for Stem Cell Research (ISSCR) Annual Meeting

A sponsored session will feature Dr. Alex Hastie from Bionano, Dr. Suk See De Ravin from National Institute of Health…

12 months ago

Finch Announces Reverse Stock Split of Common Stock

BOSTON, June 09, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a…

1 year ago

Bionano Announces Commercial Release of New Kits for its Ionic System featuring New Chemistry for Nucleic Acid Extraction from FFPE and Tumor Tissue

SAN DIEGO, June 06, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the commercial release of new kits…

1 year ago

Sharecare reveals finalists in the 2023 Sharecare Awards

General public invited to vote for Sharing Care Award through June 16; winner announced live on stage at HLTH 2023…

1 year ago

SciSparc Announces Successful Final Phase IIa Results, Meeting End Points of its Phase IIa Alzheimer Disease Patients with Agitation Trial

Topline results using the Company's SCI-110 met the trial’s primary and secondary end points, demonstrating high safety profile and reduced…

1 year ago

SciSparc Makes Another Step Towards Unlocking Potential Value Appoints New Strategy and Business Development VP

As part of the Company's corporate restructuring plan, Mr. Yaki Baranes will facilitate identifying new business opportunities TEL AVIV, Israel,…

1 year ago